Abstract
Purpose. To investigate in vitro the mechanisms involved in the gastrointestinal absorption of the HIV protease inhibitor, saquinavir mesylate (Invirase®), whose oral bioavailability is low, variable, and significantly increased by co-administration with ritonavir, also an HIV protease inhibitor but with higher oral bioavailability.
Methods. Confluent epithelial layers of human Caco-2 cells mimicking the intestinal barrier.
Results. Both saquinavir and ritonavir showed polarized transport through Caco-2 cell monolayers in the basolateral to apical direction (secretory pathway), exceeding apical to basolateral transport (absorptive pathway) by factors of 50-70 and 15-25, respectively. Active efflux was temperature dependent, saturable and inhibited by verapamil and cyclosporin A. Saquinavir and ritonavir decreased each other's secretory permeability and hence elevated their net transport by the absorptive pathway.
Conclusions. Saquinavir and ritonavir are both substrates for an efflux mechanism in the gut, most likely P-glycoprotein, which acts as a counter-transporter for both drugs. Together with sensitivity to gut-wall metabolism by cytochrome P-450 3A, this may partially account for the low and variable oral bioavailability of saquinavir in clinical studies and for its increased bioavailability after co-administration with ritonavir.
Similar content being viewed by others
REFERENCES
S. Noble and D. Faulds. Saquinavir; A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52:93–112 (1996).
J. M. Schapiro, M. A. Winters, F. Stewart, B. Efron, J. Norris, M. J. Kozal, and T. C. Merigan. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann. Intern. Med. 124:1039–1050 (1996).
D. J. Kempf, K. C. Marsh, J. F. Denissen, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484–2488 (1995).
D. Norbeck, G. Kumar, K. Marsh, et al. Ritonavir and saquinavir: potential for two-dimensional synergy between HIV protease inhibitors (abstract no. LB-7). 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 9 USA, Sep 17–20, (1995).
A. Hsu, G. R. Grannermann, E. Sun, C P. Chen, T. El-Shourbagy, C. Locke, P. Barold, L. Carothers, G. Cao, J. Quian, D. Pizzuti, F. Stewart, and J. Leonard. Assessment of single-and multiple-dose interactions between ritonavir and saquinavir. XI. International Conference on AIDS, Vancouver, Canada, July. 7–12, (1996).
U. A. Germann. P-glycoprotein — a mediator of multidrug resistance in tumour cells. Eur J. Cancer 32A:927–944 (1996).
I. K. Pajeva, M. Wiese, H.-P. Cordes, and J. K. Seydel. Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability. J. Cancer. Res. Clin. Oncol. 122:27–40 (1996).
G. Ecker and P. Chiba. Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein — an overview. Wien. Klin. Wochenschr. 107/22:681–686 (1997).
J. Hunter, B. H. Hirst, and N. L. Simmons. Drug absorption limited by p-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 10:743–749 (1993).
G. Fricker, J. Drewe, J. Huwyler, H. Gutmann, and C. Beglinger. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro — in vivo correlation. Br. J. Pharmacol. 118:1841–1847 (1996).
J. Hunter, M. A. Jepson, T. Tsuruo, N. L. Simmons, and B. H. Hirst. Functional expression of p-glycoprotein in apical membranes of human intestinal Caco-2 cells. J. Biol. Chem. 268:14991–14997 (1993).
P. Wils, V. Phung Ba, A. Warnery, D. Lechardeur, S. Raeissi, I. J. Hidalgo, and D. Scherman. Polarized transport of docetaxel and vinblastine mediated by p-glycoprotein in human intestinal epithelial cell monolayers. Biochem. Pharmacol. 48:1528–1530 (1994).
K. Hosoya, K. Kim, and V. H. Lee. Age-dependent expression of p-glycoprotein gp170 in Caco-2 cell monolayers. Pharm. Res. 13:885–890 (1996).
J. Ficorilli, B. Anderson, F. Thompson, and J. D. Fondacaro. Effects of co-solvents on mannitol permeability in Caco-2 monolayers. Pharm. Res. 13Suppl S-411 (1996).
P. Artursson. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79:476–482 (1990).
P. Artursson, J. Karlsson, G. Ocklind, N. Schipper. Shaw, A. “Cell culture models of epithelia”. A practical approach. IRL Press, 1996, pp. 111–133.
A. Tsuji, I. Tamai, A. Sakata, Y. Tenda, and T. Terasaki. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P glycoprotein. Biochem. Pharmacol. 46:1096–1099 (1993).
P. F. Augustijns, T. B. Bradshaw, L.-S. L. Gan, R. W. Hendren, and D. R. Thakker. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Comm. 197:360–365 (1993).
G. Krishna, W. H. Barr, and C. O. Watlington. The evaluation of cytochrome P4503A4 activity in Caco-2 monolayers. Pharm. Res. 13Suppl: S–n439(1996).
L. S. Gan, M. A. Moseley, B. Khosla, P. F. Augustijns, T. P. Bradshaw, R. W. Hendren, and D. R. Thakker. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug. Metab. Dispos. 24:344–349 (1996).
Hoffmann-La Roche (Welwyn). A four-week oral combination toxicity and toxicokinetic study of Ro31-89591/A12 (Saquinavir®) and A-84538 (Ritonavir) in dogs (1996) (Data on file).
V. J. Wacher, C.-Y. Wu, and L. Z. Benet. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogenesis 13:129–134 (1995).
L. Z. Benet, C.-Y. Wu, M. F. Henert, and V. J. Wacher. Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J. Control. Release 39:139–143 (1996).
C. T. Ueda, M. Lamaire, G. Gsell, P. Misslin, and K. Nussbaumer. Apparent dose-dependent oral absorption of cyclosporin A in rats. Biopharm. Drug Dispos. 5:141–151 (1984).
G. Moyle and B. Gazzard. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 51:701–712 (1996).
G. N. Kumar, A. D. Rodrigues, A. M. Buko, and J. F. Denissen. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:423–431 (1996).
D. Leveque and F. Jehl. P-glycoprotein and pharmacokinetics. Anticancer Res. 15:331–336 (1995).
A. Tsuji, I. Tamai, A. Sakata, Y. Tenda, and T. Terasaki. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Blochem. Pharmacol. 46:1096–1099 (1993).
J. Levin. Protease-Protease Studies: preliminary data from nelfinavir/saquinavir. NATAP Reports 1, Special Issue covering the 4th Conference on Retroviruses and Opportunistic Infections (1997).
Nelfinavir: general information, study results (CD4 and viral load), dosing schedule, eating instructions, drug interactions, combination with other protease inhibitors and NNRTIs, side effects, resistance, cross resistance. Information provided by National AIDS Treatment Advocacy Project (NATAP) (1997) (http://www.aidsnyc.org/natap/drug/nelfpkg.html).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alsenz, J., Steffen, H. & Alex, R. Active Apical Secretory Efflux of the HIV Protease Inhibitors Saquinavir and Ritonavir in Caco-2 Cell Monolayers. Pharm Res 15, 423–428 (1998). https://doi.org/10.1023/A:1011924314899
Issue Date:
DOI: https://doi.org/10.1023/A:1011924314899